





Smart Wearable and Autonomous Negative pressure device for wound monitoring and therapy

SWAN-iCare

Marco Romanelli Fabio Di Franscesco

MNBS 2014 – Innovation & User involvement session

21-22 Oct 2014 Toulouse, France

Consortium







Commissariat à l'Energie Atomique et aux Energies Alternatives





Heamopharm Biofluids

European Wound Management Association Secretariat

csem

Centre Suisse d'Electronique et de Microtechnique SA



Institute of Communications and Computer Systems

Smith & Nephew

ALING NI - I343

University of Pisa

Smith&nephew



CHU Grenoble







EURORESEARCH

Euroresearch

Assessing wound healing









HUMAN

CELL



SENSORS



Purpose of wound assessment

- Initial definition/diagnosis
- Clinical decision support
- Monitoring for infection
- Monitoring the effect of treatment
- Prediction of outcome
- Re-imbursement



Unique value SWAN-iCare compared against other NPWT systems





Transepidermal water loss sensor

Damaged skin looses the barrier function \rightarrow TEWL increases



TEWL $\propto \frac{\Delta RH}{\Delta x}$, RH = relative humidity, x = distance from the skin.



SWAN-iCare workflow



Expected Impact: the patient

Benefits for the patient

- Continuous home monitoring of a number of wound parameters
- Personalised therapy initiated by the physician remotely and adapted to the daily measurements
- Faster wound healing due to the early identification and therapy of potential problems
- Wound deterioration can be identified early and acted upon, therefore leading to reduced morbidity and amputation rates
- Reduced disturbance to patients life and possible need for hospitalisation
- Better quality of life with better mobility, more comfort ,less stress





Expected Impact: Society and Healthcare

Benefits for society and healthcare

- Reduced healthcare costs as a result of reduced need for hospitalisation
- Reduced burden for the patients relatives due to faster wound healing and remote monitoring
- Reduced social costs and improved productivity as the patient returns to work earlier
- Increased access to best practice wound care for patients living in remote geographical locations
- Reduced daily nursing visits allows for more new patients' to be added to the case load









Expected Impact: Medical science

Benefits for the medical science



- Advancement of wound care best practice, supply of the most effective wound care protocols available
- Continuous objective measurement contributing to evaluation of wound progress, and treatment effectiveness
- A better understanding of wound healing due to creation of a DATA base of continuous wound parameter measurements
- Potential for new wound healing research



Innovation process and Road to exploitation

- SWAN-iCare plans direct exploitation to the wound management market, organised by S&N (partner with direct access to the market)
- Road to exploitation is coherent with the target users: the SWAN-iCare road builds upon existing service delivery models of S&N



Distance to the market

- SWAN-iCare has completed 26 months out of a total of 48 months. After the end of the project, it is expected that the time needed to bring SWAN-iCare to the market is between 18 and 36 months
- The business plan of the project has identified the following steps that will be followed after the end of the project
 - o Regulatory approval (CE marking, etc.)
 - o Purchases of supplies, materials, inward shipping
 - o Manufacturing, quality assurance, packaging and dispatch
 - o Warehouse, distribution and returns/recycling routes
 - o Marketing activities
 - Integration with existing IT systems (telemonitoring modules of the system)
 - o User training



Summary

Improved wound assessment Better prediction of healing rates Improved documentation Improved decision-making Improved patient outcomes

